The MultiMalVax CALL is for a suitable European clinical trial site for the conduct of a phase I clinical trial to assess the safety, immunogenicity and ex-vivo efficacy of simian adenovirus (ChAd63) and Modified Vaccinia Ankara (MVA) vectors expressing mosquito stage Plasmodium falciparum antigens. This clinical trial will start in January 2015, enrol 24 volunteers, and should be conducted within 12 months. University of Oxford will act as sponsor of the clinical trial.
Do not wait to register for the workshop organised by the European Vaccine Initiative:
Malaria Vaccine Development in Europe – preparing for the future
20 – 21 November 2014
Louise Centre, Av. Louise 287, Brussels, Belgium
The next ‘Vaccinology in Africa Master’s Level Course’ will take place 13-17 Oct 2014 at the International Livestock Research Institute (ILRI), in Nairobi, Kenya. The course is jointly organised by the Jenner Institute, University of Oxford, the International Livestock Research Institute (ILRI) and the Fondation Mérieux, with financial support from the Jenner Vaccine Foundation, Fondation Mérieux, GlaxoSmithKline, and other funders.
A press released will be launched soon by RCSI announcing that it is to host EVI's Scientific Advisory Committee and Board meetings on 28 and 29 April respectively.
Since 2011 the European Vaccine Initiative (EVI, Germany), the University of Copenhagen (Denmark), and the Institut national de transfusion sanguine (INTS) have joined forces to define rational decision criteria for pursuing vaccine development, including the identification of relevant immunological assays for assessing immunogenicity and efficacy of two vaccine candidates in placental malaria. Full press release and video http://youtu.be/3z8a96dvJkw
- 1 of 14